Get the Stockscreener App
40.39
1.69%
0.67
After Hours:
41.00
0.61
+1.51%
Cogent Biosciences Inc stock is traded at $40.39, with a volume of 2.88M.
It is up +1.69% in the last 24 hours and up +166.95% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$39.72
Open:
$39.72
24h Volume:
2.88M
Relative Volume:
0.99
Market Cap:
$5.75B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-16.67
EPS:
-2.4234
Net Cash Flow:
$-234.65M
1W Performance:
+15.60%
1M Performance:
+166.95%
6M Performance:
+737.97%
1Y Performance:
+319.64%
1-Day Range:
$39.59
$40.75
1-Week Range:
$34.54
$40.75
52-Week Range:
$3.72
$40.75
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
40.39 | 6.10B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week HighWhat's Next? - MarketBeat
Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Biotech Star Cogent Rides High On Breakthrough Trial Hopes - Finimize
Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Finviz
Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So - Insider Monkey
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences (NASDAQ:COGT) Sets New 12-Month HighStill a Buy? - MarketBeat
Technical Reactions to COGT Trends in Macro Strategies - news.stocktradersdaily.com
Mintz Advises on Cogent Biosciences Inc.’s Concurrent Public Offerings of $345 Million of Common Stock and $230 Million in Aggregate Principal Amount of 1.625% Convertible Senior Notes Due 2031 - Mintz
Cogent Biosciences stock hits 52-week high at 36.31 USD By Investing.com - Investing.com Canada
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Yahoo Finance
Cogent Biosciences stock hits 52-week high at 36.31 USD - Investing.com India
What earnings revisions data tells us about Cogent Biosciences Inc.Earnings Beat & Reliable Trade Execution Plans - newser.com
Cogent Biosciences : COGT Jefferies London 2025 - MarketScreener
Comparing Cogent Biosciences Inc. in custom built stock radarsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Cogent Biosciences Completes $230M Convertible Notes Offering - TipRanks
[8-K] Cogent Biosciences, Inc. Reports Material Event | COGT SEC FilingForm 8-K - Stock Titan
Cogent Biosciences, Inc. Bonds — Corporate Bond Rates - TradingView
Will Cogent Biosciences Inc. stock maintain dividend yield2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Profund Advisors LLC Has $145,000 Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT6232219 Bond Analysis — Key Metrics - TradingView
COGT6232219 Bond Price and Chart — FINRA:COGT6232219 - TradingView
Cogent Biosciences: Soaring On Blowout GIST DataI Expect More Upside (NASDAQ:COGT) - Seeking Alpha
427,342 Shares in Cogent Biosciences, Inc. $COGT Purchased by Candriam S.C.A. - MarketBeat
FY2025 Earnings Estimate for COGT Issued By HC Wainwright - MarketBeat
10 Market Movers That Made Millionaires in a Week - Insider Monkey
Can Cogent Biosciences Inc. stock rebound after recent weaknessWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - Finviz
Can Cogent Biosciences Inc. stock weather global recessionWeekly Trading Summary & Real-Time Volume Analysis - newser.com
Is Cogent Biosciences Inc. stock a buy before product launchesJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Fox Run Management L.L.C. Trims Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
How Cogent Biosciences Inc. stock benefits from tech adoptionTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
COGT6232219 Bond Coupon Analysis — Rate & Payments - TradingView
Is Cogent Biosciences Inc a good long term investmentMarket Correction Analysis & Free Dashboard to Track Market Momentum - earlytimes.in
COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - The Manila Times
HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation - Nasdaq
Top Biotech Stocks To Follow TodayNovember 12th - MarketBeat
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):